These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 20482488)

  • 1. Antisense treatment in human prostate cancer and melanoma.
    Di Cresce C; Koropatnick J
    Curr Cancer Drug Targets; 2010 Sep; 10(6):555-65. PubMed ID: 20482488
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of antisense oligonucleotides targeting the cytoprotective gene, clusterin, to enhance androgen- and chemo-sensitivity in prostate cancer.
    Gleave M; Miyake H
    World J Urol; 2005 Feb; 23(1):38-46. PubMed ID: 15770517
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Custirsen (OGX-011): a second-generation antisense inhibitor of clusterin in development for the treatment of prostate cancer.
    Zielinski R; Chi KN
    Future Oncol; 2012 Oct; 8(10):1239-51. PubMed ID: 23130925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oblimersen: Augmerosen, BCL-2 antisense oligonucleotide - Genta, G 3139, GC 3139, oblimersen sodium.
    Drugs R D; 2007; 8(5):321-34. PubMed ID: 17767397
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of antisense oligonucleotides targeting the antiapoptotic gene, clusterin/testosterone-repressed prostate message 2, to enhance androgen sensitivity and chemosensitivity in prostate cancer.
    Gleave ME; Miyake H; Zellweger T; Chi K; July L; Nelson C; Rennie P
    Urology; 2001 Aug; 58(2 Suppl 1):39-49. PubMed ID: 11502446
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antisense therapy: recent advances and relevance to prostate cancer.
    Benimetskaya L; Stein CA
    Clin Prostate Cancer; 2002 Jun; 1(1):20-30. PubMed ID: 15046709
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clusterin knockdown using the antisense oligonucleotide OGX-011 re-sensitizes docetaxel-refractory prostate cancer PC-3 cells to chemotherapy.
    Sowery RD; Hadaschik BA; So AI; Zoubeidi A; Fazli L; Hurtado-Coll A; Gleave ME
    BJU Int; 2008 Aug; 102(3):389-97. PubMed ID: 18336596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Oblimersen sodium (G3139 Bcl-2 antisense oligonucleotide) therapy in Waldenstrom's macroglobulinemia: a targeted approach to enhance apoptosis.
    Frankel SR
    Semin Oncol; 2003 Apr; 30(2):300-4. PubMed ID: 12720157
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antisense oligodeoxynucleotide therapy targeting clusterin gene for prostate cancer: Vancouver experience from discovery to clinic.
    Miyake H; Hara I; Gleave ME
    Int J Urol; 2005 Sep; 12(9):785-94. PubMed ID: 16201973
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Custirsen (OGX-011): clusterin inhibitor in metastatic prostate cancer.
    Al-Asaaed S; Winquist E
    Curr Oncol Rep; 2013 Apr; 15(2):113-8. PubMed ID: 23266703
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic integration of c-myc and bcl-2 antisense molecules with docetaxel in a preclinical model of hormone-refractory prostate cancer.
    Leonetti C; Biroccio A; D'Angelo C; Semple SC; Scarsella M; Zupi G
    Prostate; 2007 Sep; 67(13):1475-85. PubMed ID: 17654511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Toxicology of antisense therapeutics.
    Jason TL; Koropatnick J; Berg RW
    Toxicol Appl Pharmacol; 2004 Nov; 201(1):66-83. PubMed ID: 15519609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The potential of clusterin inhibiting antisense oligodeoxynucleotide therapy for prostate cancer.
    Miyake H; Hara I; Fujisawa M; Gleave ME
    Expert Opin Investig Drugs; 2006 May; 15(5):507-17. PubMed ID: 16634689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estimated number of off-target candidate sites for antisense oligonucleotides in human mRNA sequences.
    Yoshida T; Naito Y; Sasaki K; Uchida E; Sato Y; Naito M; Kawanishi T; Obika S; Inoue T
    Genes Cells; 2018 Jun; 23(6):448-455. PubMed ID: 29667281
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Subcellular trafficking of antisense oligonucleotides and down-regulation of bcl-2 gene expression in human melanoma cells using a fusogenic liposome delivery system.
    Hu Q; Bally MB; Madden TD
    Nucleic Acids Res; 2002 Aug; 30(16):3632-41. PubMed ID: 12177306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Phase I pharmacokinetic and biological correlative study of oblimersen sodium (genasense, g3139), an antisense oligonucleotide to the bcl-2 mRNA, and of docetaxel in patients with hormone-refractory prostate cancer.
    Tolcher AW; Kuhn J; Schwartz G; Patnaik A; Hammond LA; Thompson I; Fingert H; Bushnell D; Malik S; Kreisberg J; Izbicka E; Smetzer L; Rowinsky EK
    Clin Cancer Res; 2004 Aug; 10(15):5048-57. PubMed ID: 15297406
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting different signaling pathways with antisense oligonucleotides combination for cancer therapy.
    Leonetti C; Zupi G
    Curr Pharm Des; 2007; 13(5):463-70. PubMed ID: 17348843
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oblimersen Bcl-2 antisense: facilitating apoptosis in anticancer treatment.
    Klasa RJ; Gillum AM; Klem RE; Frankel SR
    Antisense Nucleic Acid Drug Dev; 2002 Jun; 12(3):193-213. PubMed ID: 12162702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized phase II and pharmacokinetic study of the antisense oligonucleotides ISIS 3521 and ISIS 5132 in patients with hormone-refractory prostate cancer.
    Tolcher AW; Reyno L; Venner PM; Ernst SD; Moore M; Geary RS; Chi K; Hall S; Walsh W; Dorr A; Eisenhauer E
    Clin Cancer Res; 2002 Aug; 8(8):2530-5. PubMed ID: 12171880
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antisense targets to enhance hormone and cytotoxic therapies in advanced prostate cancer.
    Gleave M; Nelson C; Chi K
    Curr Drug Targets; 2003 Apr; 4(3):209-21. PubMed ID: 12643471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.